Research programme: anticancer therapeutics - MerLion
Alternative Names: Macrolide programme - MerLionLatest Information Update: 04 Nov 2017
At a glance
- Originator Combinature Biopharm
- Developer MerLion Pharmaceuticals
- Class Macrolides; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany
- 19 Jan 2011 Preclinical development is ongoing Germany
- 19 Jan 2011 Research programme: anticancer therapeutics - MerLion is available for licensing as of 19 Jan 2011. http://www.merlionpharma.com/